New drug combo shows promise for rare esophageal cancer
NCT ID NCT07155122
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 25 times
Summary
This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can help shrink tumors in people with a rare type of esophageal cancer. About 15 adults with limited-stage small cell carcinoma of the esophagus will receive the combination, then have surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL CARCINOMA OF THE ESOPHAGEAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.